Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 18th Annual Pharma Middle East Congress Radisson Blu Hotel, Yas Island, Abu Dhabi, UAE.

Day 2 :

  • Pharmaceutics
Location: Abu Dhabi

Session Introduction

Ibrahim Elsayed

Gulf Medical University, UAE

Title: Design of Pharmaceutical Experiments Using Design Expert® Software
Speaker
Biography:

Dr Ibrahim Elsayed is an associate professor and chair of Pharmaceutical Sciences department at Gulf Medical University, Ajman UAE. He did his PhD in Pharmaceutics and Industrial Pharmacy from Cairo University in 2011 and graduation diploma in Health-Professions Education from Gulf Medical University in 2015. He has experience in teaching almost all pharmaceutics courses including dosage forms, biopharmaceutics, pharmacokinetics, reaction kinetics, industrial pharmacy, quality control and assurance. As an administrator, he did preparation of the self-study report for CAA accreditation and ACPE certification, Developing integrated pharmacy curricula., Preparation of the college strategic plan 2017-2022, Participation in employment, quality assurance, assessment and curriculum committees, Developing and monitoring course and instructor online evaluation forms, Preparation and revision of course syllabi and files, Creating lectures and exams timetables using advanced software, Establishing nanotechnology research and IV skills labs.

Abstract:

The seminar gives an introduction to Design Expert® software to enable the audience to start using it. This software is a professional statistical tool used to create the experimental design, study the effects of different factors with the least possible number of trials and optimize the designed process through simultaneous selection of the desired level of each independent variable. Different statistical plans can be utilized as full factorial, response surface and mixture designs. The response surface is the most commonly used design in pharmaceutical research and it includes different sub-designs; e.g. central composite and Box-Behnken. Before starting the experimental part, the studied factors and traced responses are loaded into the Design Expert® software to determine the number and compositions/conditions of the experimental trials. After finishing the experimental work, the obtained data are fed into the software to assign different desirability values to the conducted experimental trials. Consequently, we can select the optimum trial having the maximum desirability value to be subjected to further investigations.

 

  • Insights of Pharmacology & Cancer Therapeutics
Location: Abu Dhabi

Session Introduction

Rashida Muhammad Umar

Istanbul Medipol University, Turkey

Title: Comprehensive medication management in Oncology patients
Speaker
Biography:

Rashida Muhammad Umar is an assistant professor at Istanbul Medipol University, Istanbul. She earned her first degree in pharmacy from Hacettepe University Ankara in 2011 and her PhD in clinical pharmacy from Marmara University Istanbul in 2017. She is a dedicated lecturer focused on the improvement of pharmacy education and the application of clinical pharmacy in the health care system.

 

Abstract:

Cancer is one of the leading causes of death globally with increasing prevalence.  Treatment in cancer patients is complicated as it obliges the use of drugs with narrow therapeutic window and high toxicity to treat cancer, in addition to supportive care medications to treat disease-related and therapy complications and also comorbidities. As such cancer patients are prone to drug-related problems. Comprehensive medication management (CMM) is defined by the American College of Clinical Pharmacy as “the standard of care that ensures each patient's medication (including non-prescription drugs, traditional and alternative therapies and supplements) are individually assessed to determine that each medication is appropriate for the patient, effective for the medical condition, safe given to comorbidities and other medications are taken, and able to be taken by the patient as intended”. 

Speaker
Biography:

Dr Minoo Shahidi is an academic member of the Hematology group at the Iran University of Medical Sciences (IUMS). In 2010, she achieved her PhD from the University of Surrey, UK. During her several year careers as a lecturer at IUMS, she published a number of books and papers. In addition, she conducted some projects and received certificates of the invention. She also dedicates herself in providing help to her postgraduate students as well as to professionals and offers tutorials for them to pass their thesis via her projects in the field of novel treatment approaches for leukaemia and hemostasis.

Abstract:

Statement of the Problem: Since human umbilical vein endothelial cells (HUVEC) can be simply collected, developing of hematopoietic progenitor cells from these cells may improve hematopoietic cell engraftment for irregular cases with limitations for receiving compatible blood components. Regenerative functions of Silymarin, a mixture of polyphenolic flavonoids derived from milk thistle, have been reported previously. Accordingly, there are some reports of Silymarin effect in regeneration and treatment of skin disorders, but no effect of this polyphenolic flavonoid on hematopoietic cells has been reported so far. The purpose of this study was to investigate the direct effect of Silymarin on conversion of HUVEC to hematopoietic cells. The effect of Silymarin on all the main hematopoietic lineage markers in HUVEC was investigated after 24h by flow cytometry and immunocytochemistry. Treatment of endothelial cells with Silymarin after 24h significantly increased the number of the cells expressing hematopoietic progenitor markers. However, no significant expression of the lineage-specific markers was found during 24h. Taken together, our in vitro findings revealed the potential of Silymarin to switch human 

  • Clinical Pharmacy & Pharmaceutical Care
Speaker
Biography:

Dr Anmar AL-TAIE is a teaching faculty member in clinical pharmacy discipline both practical and theoretical academic platforms at pharmacy department-Osol Aldeen University College. He finished his PhD study in Clinical at Marmara University- Faculty of Pharmacy- Clinical Pharmacy Department. He also finished his MSc in clinical pharmacy and BSc in pharmacy at Baghdad University –College of Pharmacy. He conducts many studies in fields of clinical pharmacy practice that were published in reputed journals and international conferences and is as an active reviewer in a number of reputed journals (such as the International Journal of Clinical Pharmacy and Supportive Care in Cancer). He has several participations in local and global activities regarding clinical pharmacy discipline.

 

Abstract:

Diabetes mellitus (DM) and cancer are considered as severe complicated conditions that can pose an additional significant clinical challenge and have a tremendous impact on health. The vast majority of DM cases are type 2, which are associated largely with older overweight age patients and those with family history. Studies showed that comorbid medical conditions such as DM affect 8-18% of all cancer patients. Such patients have fewer reserves in their body to fight against the various complications, such as infections. Moreover, chemotherapy could exacerbate pre-existing diabetes and induce hyperglycaemia especially in patients who already had a propensity toward developing the disease while their side effects can make it more difficult to keep blood glucose levels in control. Furthermore, stress accompanied the disease itself and the use of corticosteroids during chemotherapy, as part of the antiemetic regimes or to prevent allergic reactions caused by some chemotherapy drugs may be continued after chemotherapy for a certain period of time. Steroids can raise blood glucose levels pretty markedly and a few days of hyperglycaemia contribute to the uncontrolled DM in patients undergoing chemotherapy. In this regard, diabetes treatments need to be adjusted, especially around the time that the steroids are given. 

  • Pharmaceutical Biotechnology & rDNA Technology
Speaker
Biography:

Kriti Ray, M. Sc. She is pursuing her Ph.D. under the Deakin India Research Initiative (DIRI) program initiated between Reliance Institute of Life Sciences, India and Deakin University, Australia. Her study focuses on developing reporter assays for antibody-based therapeutics. She has also worked with siRNA-based therapeutics against cancer and dengue.

Abstract:

Aim of the study: Biopharmaceuticals will comprise around 27% of the global pharmaceutical market in the near future, and monoclonal antibodies (mAbs) are predicted to take the major share due to their favourable drug properties such as specificity, high efficacy and fewer side-effects. Hence, testing mAbs for their efficacy and stability before batch release is an important aspect of the mAb development and manufacturing program. Here, we aim to design and validate an in-vitro reporter gene-based assay for the evaluation of anti-IL6/IL6R and anti-EGFR mAbs with immense therapeutic potential and to make the stability testing procedure more robust, precise and rapid in comparison to existing assays.

 

  • Cardiac & Neuro Pharmacology
Location: Abu Dhabi
Speaker
Biography:

Maha AlMolaiki was graduated from King Saud University(KSU) with Pharm.D. degree, an employee in King Abdulaziz Medical City-Central Region(KAMC-CR) since 2014, who assists in patient care, both in outpatient and inpatient settings, joined the pharmacy residency program in 2016, currently pharmacy resident. Had two publications.

Abstract:

Aim: to assess the likelihood of developing new-onset ischemic stroke among patients who were using PPIs for 6 months or more versus patients who were not using PPIs. 

Background: Stroke is a rapid loss of brain function due to disruption of blood supply to the brain and a major cause of mortality and morbidity worldwide. In Saudi Arabia, the incidence of ischemic strokes is 69%. The established risk factors are hypertension, diabetes mellitus, smoking, dyslipidemia. Proton pump inhibitors (PPIs) one of the world’s most frequently prescribed medications contributed to many adverse effects. In 2016, a retrospective study found a significant increase in the risk of new onset ischemic stroke in the PPIs users. In 2018, a prospective cohort study found no association.